“a favorable trend”

As a result, the OS benefit showed a favorable trend for the afatinib group compared with the osimertinib group, as shown in Figure 3 , and Supplementary Figure S4 , available at https://doi.org/10.1016/j.esmoop.2021.100115 .

Comparing GBmol and GBhisto cases receiving RT/CT revealed no significant differences in survival, albeit especially in the cohort of biopsy-only cases, a favorable trend was detectable ( Figure 1E , F ).

While no significant difference in the re-bleeding rate was appreciated, there was a favorable trend toward decreased re-bleeding in the TXA group [ 86 ].

In patients whose tumors carried wild-type PIK3CA , erlotinib plus GEMOX showed a favorable trend for overall response, but no statistically significance difference ( P = .08).

reported improved patient understanding and a favorable trend in readmission outcomes after the systematic implementation of Teach-Back as part of the discharge process [ 20 ].

A favorable trend of oil displacement occurs when: (1) k rw μ w k ro μ o = M ≤ 1 where M is the mobility ratio, μ w is the water viscosity (mPa·s), μ o is the oil viscosity (mPa·s), and k rw and k ro are the relative permeabilities of water and oil, respectively (mD).

The addition of PORT to surgery displayed a favorable trend suggesting a possible clinical benefit on LC.

Interim analysis revealed a significant improvement in radiographic progression-free survival and a favorable trend in overall survival.

In this regard, although the result of the second category shows a favorable trend towards ST on active JPS, the effect is not significant.

The combination of imlunestrant and abemaciclib did not demonstrate a confirmed OS benefit (HR 0.82; 95% CI, 0.59–1.16), but a favorable trend was observed [ 12 ].

The results showed a favorable trend for depressive symptom reduction, but the overall evidence remained uncertain.

Although a favorable trend was seen in the pembrolizumab monotherapy group, the difference was not significant.

Additionally, in IABP-SHOCK II, there was observed a favorable trend with IABP in younger patients and in those with a first MI.

In the GOURMET-HF (Geriatric Out-of-Hospital Randomized Meal Trial in HF) trial, 4 weeks of home-delivered sodium-restricted DASH meals in 66 patients (age, 71 ± 8 years; 30% women; BMI, 33 ± 8 kg/m 2 ; EF, 39 ± 18%, 1500 mg sodium/day) versus usual care showed a favorable trend in rehospitalization in 30 days [ 54 ].

c) Total infection rates varied substantially between studies, with no infections occurring in the small cohort treated with the Compress implant and seemingly showing a favorable trend of implant infections (Grade 4) for the screw over the press-fit implant (screw: 2–11%, press-fit: 0–29%); although these numbers, again, are greatly affected by transtibial implants in which there is less expertise.

Constipation outcomes suggested a favorable trend associated with physiotherapy, consistent with evidence linking mobility and physical activation with bowel regulation (Helgesen et al. 2024 ; Cui et al. 2024 ).

Moreover, there is a favorable trend in AHT group, which may be due to improved reperfusion after thrombolysis.

Although the trial was not designed or powered to detect statistically significant changes, exploratory data among those with follow‐up data demonstrated a favorable trend in alcohol intake and liver function outcomes with ILC engagement.

Because this meta-analysis revealed an I 2 value of 0%, indicating low statistical heterogeneity among the included studies, the pooled results suggested a favorable trend toward a reduced risk of OM in patients receiving chemotherapy.

The 2 RCTs showed a favorable trend toward greater PCa detection when a combination of systematic biopsies and RTE-targeted biopsies was used than when systematic biopsy alone was used (45.5% vs 39.5%, risk ratio (RR) 1.18, 95% CI 0.98–1.43).

PT for EBC showed a favorable trend for OS compared with XT, but no clear superiority was observed.

Despite the lack of statistical significance, this observed reduction reflects a favorable trend toward improved microvascular outcomes with semaglutide and is clinically relevant, as the prevention of microvascular outcomes is a critical concern in the management of T2D.

Although there is a favorable trend, thrombopoietic agents did not significantly decrease dose delays and/or reductions compared with placebo or no treatment (21.1% [95% CI: 10.8%, 37.0%] vs 40.4% [95% CI: 9.6%, 81.2%], P = 0.364) ( Fig 2 , Table 2 ).

Additionally, while there was a favorable trend toward a reduction in urinary albumin-to-creatinine ratio (UACR) in the ocedurenone group, this change did not reach statistical significance within the study period [ 73 ].

Corrected resampled t -tests confirm improved performance over the non-sequential Transformer, while the comparison with XGBoost indicates a favorable trend without conclusive evidence.